• CordenPharma & Dharmacon have entered a strategic collaboration for accelerated oligonucleotide synthesis

    A unique, end-to-end solution to address the need for a simplified, faster development process is here!

    CordenPharma & GE Healthcare enter a strategic collaboration.

    A new strategic collaboration between CordenPharma International and Dharmacon will address the challenges of time and capacity when moving from the research and preclinical stages to oligonucleotide-based drug development and clinical trials. This transition typically requires the transfer of technology from an oligonucleotide vendor to a contract manufacturing organization, but capacity issues in the biotech contract manufacturing marketplace often create a bottleneck. The collaboration between CordenPharma and Dharmacon will provide biotech and pharmaceutical customers with a new option to address these challenges.

    “Through this agreement, we are bringing Dharmacon’s product line, which offers leading technical expertise in research-scale design and manufacturing, together with CordenPharma’s deep experience in contract manufacturing,” said Olivier Loeillot, General Manager of GE Healthcare’s Genomics & Cellular Research business. “We can help customers move faster by working together and provide an offering that takes them from bench to batch with one partner.”

    CordenPharma International VP of Global Marketing & Sales Michael Quirmbach commented, “This collaboration will further strengthen our newly created service offering in the Oligonucleotide manufacturing field and will uniquely position CordenPharma and Dharmacon in this growing pharmaceutical market segment. Customers will be able to benefit from an efficient end-to-end solution, including drug product supply.

    Learn more about this exciting collaboration that will accelerate oligonucleotide-based drug discovery by viewing the complete press release.

    Additional Resources

Share: